BMO Capital Markets initiated coverage on Seagen with a new price target
$SGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BMO Capital Markets initiated coverage of Seagen with a rating of Market Perform and set a new price target of $169.00